《pharmed》
Part I - Chemotherapy
1
Oncology Performance Status
1.1
Karnofsky Performance
1.2
Lansky Performance
1.3
ECOG Performance
2
Chemotherapy Dosage Based on Hepatic Function
2.1
Recommended Dose Reduction for Hepatic Dysfunction
3
Chemotherapy Dosage Based on Renal Function
3.1
Recommended Dose Reduction for Renal Dysfunction
4
Dialysis of Chemotherapy Drugs
4.1
Guidelines for Dialysis of Chemotherapy Drugs
5
Common Chemotherapy Regimens
5.1
ADRENOCORTICAL CANCER
5.2
ANAL CANCER
5.3
BASAL CELL CANCER
5.4
BILIARY TRACT CANCER
5.5
BLADDER CANCER
5.6
BRAIN CANCER
5.7
BREAST CANCER
5.8
CANCER OF UNKNOWN PRIMARY
5.9
CARCINOID TUMORS AND NEUROENDOCRINE TUMORS
5.10
CERVICAL CANCER
5.11
COLORECTAL CANCER
5.12
ENDOMETRIAL CANCER
5.13
ESOPHAGEAL CANCER
5.14
GASTRIC CANCER
5.15
GASTROINTESTINAL STROMAL TUMOR (GIST)
5.16
HEAD AND NECK CANCER
5.17
HEPATOCELLULAR CANCER
5.18
KAPOSI’S SARCOMA
5.19
LEUKEMIA
5.20
LUNG CANCER
5.21
LYMPHOMA
Part II - Oncology
6
Prostate Cancer
6.1
Staging System for Prostate Cancer
6.2
Diagnosis - prostate cancer
6.3
Treatment - prostate cancer
6.4
Principles of Genetics - prostate cancer
6.5
Principles of Imaging - prostate cancer
6.6
Principles of Active Surveillance and Observation
6.7
Principles of Radiation Therapy
6.8
Principles of Surgery
6.9
Principles of Androgen Deprivation Therapy
6.10
Part III - Diabetes Mellitus
Part IV - Geriatrics
Part V - Others
7
ICD 10 CM
7.1
國際疾病分類第十版中英對照檢索
8
TFDA ATC
8.1
藥品藥理治療分類 ATC Code
9
TFDA AHFS/DI
9.1
藥品藥理治療分類 AHFS/DI Code
10
Frequently Used Links
10.1
醫藥參考
10.2
醫藥文獻
10.3
藥物辨識
10.4
藥品給付
11
Memo
11.1
Daily
11.2
Code
7
ICD 10 CM
International Classification of Diseases, Tenth Revision, Clinical Modification
7.1
國際疾病分類第十版中英對照檢索